Hashimoto’s disease, which is associated with thyroid ophthalmopathy: a case report

Yıl 2020, Cilt: 12 Sayı: 1, 120 - 123, 01.03.2020

Cem Onur Kıraç Suleyman Hilmi Ipekci Suleyman Baldane Banu Turgut Ozturk Levent Kebapcilar

https://doi.org/10.21601/ortadogutipdergisi.618935

Öz

Hashimoto’s disease is the most common cause of hypothyroidism. Since it is an autoimmune disease, the incidence of other autoimmune diseases has increased with Hashimoto’s disease. Extra-thyroidal involvements are also seen due to the autoantibodies that play a role in the etiopathogenesis of the disease. One of these is ophthalmopathy. We aimed to report the association of ophthalmopathy with Hashimoto’s disease which is frequently associated with Graves’ disease and to report the mechanism involved in pathogenesis in the light of literature.

Anahtar Kelimeler

Etiopathogenesis, Hashimoto’s disease, thyroid ophthalmopathy, thyroid stimulating immunoglobulin

Tiroid oftalmopatisi ile ilişkili Hashimoto hastalığı

Öz

Hashimoto hastalığı hipotiroidinin en sık sebebidir. Otoimmun bir hastalık olmasından dolayı beraberinde diğer otoimmun hastalıkların görülme sıklığı artmıştır. Hastalığın etiyopatogenezinde rol alan otoantikorlardan dolayı ekstra-tiroidal tutulumlar da görülmektedir. Bunlardan biri de oftalmopatidir. Bu vakada, sıklıkla Graves hastalığı ile ilişkilendirilen tiroid oftalmopatisinin Hashimoto hastalığı ile olan birlikteliğini ve patogenezinde rol alan mekanizmaları literatür eşliğinde sunmayı amaçladık.

Anahtar Kelimeler

Etiyopatogenez, Hashimoto hastalığı, tiroid oftalmopatisi, tiroid stimulan antikor

Kaynakça

• Scott IU, Siatkowski MR. Thyroid eye disease. Semin Ophthalmol 1999; 14; 52-61.
• Yuksel D. The etiopathogenesis of thyroid associated orbitopathy and the new insights. Turk J Ophthalmol 2007; 37: 222-7.
• Bartalena L, Pinchera A, Marcocci C. Management of graves’ ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21; 168-99.
• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223-43.
• Golden SH, Robinson KA, Saldanha I, Anton B, Ladenson PW. Clinical review: prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab 2009; 94: 1853-78.
• Delemer B, Aubert JP, Nys P, Landron F, Bouee S. An observational study of the initial management of hypothyroidism in France: the ORCHIDEE study. Eur J Endocrinol 2012; 167: 817-23.
• Pandit AA, Vijay Warde M, Menon PS. Correlation of number of intrathyroid lymphocytes with antimicrosomal antibody titer in Hashimoto’s thyroiditis. Diagn Cytopathol 2003; 28: 63-5.
• Diana T, Krause J, Olivo PD, König J, Kanitz M, Decallonne B, et al. Prevalance and clinical relevance of thyroid stimulating hormone receptro-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol 2017; 189: 304-9.
• Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, König J. Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab 2016; 101: 1998-2004.
• Ponto KA, Binder H, Diana T, Matheis N, Otto AF, Pitz S, et al. Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy. Thyroid 2015; 25: 942-8.
• Bartalena L, Faourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 2014; 37: 691-700.
• Bartley GB, Fatourechi V, Kadarmas EF, Jacobson SJ, Ilstrup DM, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121: 284-9.
• Gönen MS, Öztürk M, İpekçi S. A rare presentation of hashimoto hypothyroidism: a case with exophthalmos, clubbing, seberoic dermatitis. 32. TEMD Congress. 13-17 October 2010, Antalya, Turkey; 2010. pp.348.
• Yoshihara A, Yoshimura Noh J, Nakachi A, Ohye H, Sato S, Sekiya K, et al. Severe thyroid-associated orbitopathy in Hashimoto’s thyroiditis. Report of 2 cases. Endocr J 2011; 58: 343-8.